Patient has received prior therapy with an anti- programmed death receptor 1 (anti-PD-1), anti-PD-1- ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD- L2) agent.
Patients must have had prior treatment with anti-PD1 or anti-PD-L1 agents and had documented disease progression either while on these agents or after stopping therapy with these agents without intervening therapy; patients must have discontinued anti-PD-1 or anti-PD-L1 therapy at least 21 days prior to registration
Patients must not have achieved a confirmed partial or complete response to the anti-PD-1 or anti-PD-L1 agents prior to progression
Patients must not have had systemic therapy, excluding anti-PD-1 or anti-PD-L1 agents, within 21 days prior to registration
Patients must not have had:\r\n* Prior treatment with ipilimumab or other CTLA-4 antagonists\r\n* Systemic therapy between progression on the anti-PD-1 or anti-PD-L1 agents and registration\r\n* Note: Systemic therapy (including BRAF-targeting agents) prior to anti-PD-1 or anti-PD-L1 therapy is allowed
Prior treatment with any PARP inhibitor or any anti-PD-1/anti-PD-L1 antibody
Prior treatment with lenvatinib or any PD-1, anti-PD-L1, or anti-PD-L2 agent, excluding melanoma and NSCLC where prior treatment with one PD-1, anti-PD-L1, or anti-PD-L2 agent is allowed
No prior therapy with a CDK 4/6 inhibitor; prior anti-PD-1 and anti-PD-L1 therapy is permitted
Received any systemic therapy for cancer treatment including immunotherapeutic agents such as anti-PD1 or anti-PD-L1 antibody therapy.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Subject has already received one of the following therapy/treatment: anti-PD-1, anti-PD-L1, or anti-PD-L2 inhibitor.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2, or HSP inhibitor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; has been on any prior Merck MK-3475 (pembrolizumab) studies
Refractory to prior anti-PD-1/PD-L1 agent
The subject has received prior pembrolizumab or any other anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy, or has participated in any prior studies involving pembrolizumab
Prior treatment with lenvatinib or any anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Intolerance to prior anti-PD-1/PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent; please contact the principal investigator for further clarification if needed
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 oranti-CTLA-4 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior anti-PD-1 or anti-PD-L1 therapy may not be administered after ACT and before study atezolizumab (MPDL3280A) administration
COHORT 1: Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
COHORT 2: Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior exposure to an anti-PD-1, anti-PD-L1 or anti-PD-L2
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent (only cohort A)
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1), or anti-PD-L2 agent, or previously participated in Merck pembrolizumab (MK-3475) study
Previous treatment with any anti-PD-1, PD-L1, or PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor.
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent are not eligible
Prior anti-cancer treatments such as chemotherapy, radiotherapy, hormonal, or immunotherapy (including anti-PD-1/PD-L1) are permitted
Prior disease progression on anti-PD-1 therapy
Previous treatment with any anti-PD-1, PD-L1, or PD-L2 agent
Received prior therapy with an anti-CTLA-4, anti-PD-1, anti-PD1-ligand-1 (anti-PD-L1), or anti-PD-1 ligand-2 (anti-PD-L2) agent within 8 weeks prior to initiation of study treatment depending on study part
Prior treatment with anti-PD-1 or PD-L1 therapies
The participant has received prior pembrolizumab or any other anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy, or has participated in any prior studies involving pembrolizumab
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent\r\n* This criterion does not apply to eligibility for second course treatment
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Prior therapy with anti-PD-L1 and anti-PD1 antibodies, MEK inhibitors or MDM2 antagonists.
Prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
For Parts B and C, patients who received previous anti- PD-1, anti-PD-(L)1 treatment
Patients may not have received prior anti PD-1 or anti PD-L1 inhibitors
History of prior therapy with an IDO1 inhibitor in combination with an anti-PD-1/anti-PD-L1 agent/any other drug specifically targeting checkpoint pathways; patients who have received prior therapy with single agent anti-PD-1/anti-PD-L1 therapy or single agent IDO1 inhibitor will be eligible for this study
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (TCR) (e.g., CTLA-4, OX 40, CD137).
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD1 or anti-PD-L1 antibody therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-CTLA4 or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Previous anti-PD1 or anti-PD-L1
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent within the prior 24 weeks
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4 agent, or mifepristone
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has been receiving anti-PD-1 or anti-PD-L1 immunotherapy for at least four weeks
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent without having had evidence of objective response
Patients with prior therapy with antibodies that modulate T-cell function (e.g., anti-PD-1, anti-PD-L1)
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior immunotherapy or treatment with another anti PD 1 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Previous therapy for this cancer with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or any other immunomodulatory agent
Has received prior anti-PD-1 or anti-PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agents, or if the subject has previously participated in Merck pembrolizumab clinical trials
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Anti-PD-1, anti-PD-L1, or anti-PD-L2 agents
Has received prior therapy with an anti-PD-1, anti-PD-L-1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or sEsphB4-HSA
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has had prior treatment with any other anti-PD-1 or PD-L1 or PD-L2 agent
Prior treatment with an anti-PD-1, anti-PD-L1 or anti-PD-L2 agent
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with anti-PD1 antibody
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2
Patient had prior treatment with any other anti-PD-1, or PD-ligand (L1) or PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Patients who discontinued prior anti-PD-1/PD-L1 therapy due to an anti-PD-1/PD-L1-related toxicity.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T cell receptor
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or blinatumomab
REGISTRATION TO TREATMENT (STEP 1): Patient must not have received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent for dose expansion; (patients in dose escalation may have received an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent)
Prior therapy with anti-PD-1, PD-L1, or PD-L2 agent.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or other immune checkpoint inhibitor (e.g. anti-CTLA4)
Prior treatment with an investigational compound being tested in this study (e.g., poly ADP ribose polymerase [PARP] inhibitor, anti-PD-1, anti-PD-L1, or anti-PD-L2)
Patients may not have had any prior ipilimumab and/or anti-PD-1/PD-L1 agent in the metastatic setting
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another stimulatory or co-inhibitory T-cell receptor (eg, CTLA-4, OX-40, CD137)
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior immunotherapy including anti-programmed cell death-1 (anti-PD-1), anti-PD-ligand-1 (anti-PD-L1), or anti-PD-L2 agents, or if the participant has previously participated in Merck pembrolizumab (MK-3475) studies.
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 antibody.
Has previously participated in any other pembrolizumab (MK-3475) trial, or received prior therapy with an anti-programmed cell death 1 (anti-PD-1), anti-PD ligand 1 [anti-PD-L1], and anti-PD-L2
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in MK-3475 clinical trials.
Prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, or anti-PD-L1, or anti-PD-L2 agent or with an agent directed to another co-inhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein 4 [CTLA-4], OX-40, CD137).
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
No prior treatment with anti-PD-1 or anti-PD-L1
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in Merck MK-3475 clinical trials.
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the subject has previously participated in Merck MK-3475 clinical trials.
Prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2 agent, or agents targeting other checkpoint pathways (e.g. CTLA-4)
Has received prior immunotherapy including anti-programmed death-1 (anti-PD-1), anti-PD-ligand-1 (anti-PD-L1), or anti-PD-L2 agents, or if the participant has previously participated in clinical studies with pembrolizumab (MK-3475)
Anti PD-1/PD-L1 relapsed cohorts (I and II), participants whose most recent anti-cancer therapy consisted of single-agent PD-1/PD-L1 blockade will be enrolled
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or if the patient has previously participated in a Merck MK-3475 clinical trial.
Intolerance to prior anti-PD-1/PD-L1 therapy
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti-PD-1, PD-L1, or CTLA4, or ensartinib (X-396).
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or has participated in another Merck pembrolizumab clinical trial
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Prior therapy with a PD-1, anti-PD-Ligand 1 (PD-L1), or anti-PD-L2 agent, or previously participated in a Merck pembrolizumab (MK-3475) study
Has received prior therapy with an anti-PD-1, anti-PD-L1, anti-PD-L2, OR other immune check point agonist/inhibitor.
Prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2 monoclonal antibody.
Prior immunotherapy including anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or previously participated in Merck pembrolizumab (MK-3475) clinical trial
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent or previously participated in Merck MK-3475 clinical trial
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent, or with an agent directed to another co-inhibitory T-cell receptor
Prior therapy with an anti-PD-1 or anti-PD1-L1 or -L2 therapy or previously participated in a Merck pembrolizumab (MK-3475) trial
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody.
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Histological or cytological diagnosis of NSCLC. Patients must have 1) previously received prior anti-PD-L1 or anti-PD-1 mAb as most recent therapy, AND 2) did not have progressive disease as best overall response on recent PD-L1/PD-1 therapy (ie, stable disease 3 months, PR, or CR), AND 3) who subsequently progressed on anti-PD-L1 or anti-PD-1 mAb.
Prior exposure to any anti-PD-1 or anti-PD-L1 antibody
Prior treatment with cabozantinib or immune checkpoint inhibitors including anti-CTLA-4, anti-PD-1, anti-PD-L1, or anti-PD-L2 therapy except in Expansion Cohorts 5 and 7 in which prior anti-PD-1 or anti-PD-L1 therapy is required for eligibility. Other restrictions regarding prior therapy may apply.
Patients who received prior anti-PD-1 therapy are eligible for cohort 1 only and patients who have not received prior anti-PD-1 therapy are eligible for cohort 2 only
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
With TNBC has received prior therapy with an anti-PD-1, anti-PD-L1, anti-CTLA-4, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Tumor for which standard therapy, including approved anti-PD-1 or anti-PD-L1 therapy, when applicable, does not exist or is no longer effective.
Previous treatment with anti-PD-1, anti-PD-L1 or anti-PD-L2 therapy.
Has received prior therapy with an anti-programmed cell death (PD)-1, anti-PD-L1, or anti-PD-L2 agent
Must have received either nivolumab or pembrolizumab or a different IND-approved anti-PD1 or anti-PD-L1 therapy, unless medically contraindicated
Subjects who are treatment-naive or pretreated (prior anti-PD-1 or anti-PD-L1 required) in the recurrent/metastatic setting.
Prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2
Patient must have had prior treatment with anti-PD-1 or anti-PD-L1 agents and have documented disease progression on these agents prior to registration; patient must have received anti-PD-1 or PD-L1 based therapy as the immediate previous line of treatment and within 56 days prior to registration
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Prior treatment with anti PD-1 or PD-L1 therapy (Arm A)
Prior systemic chemotherapy within 2 weeks of planed anti-PD1 treatment.
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Subjects who are currently receiving treatment with the anti-PD-1 antibody Pembrolizumab either alone or in combination and are progressing. Subjects must have received at least 4 doses of anti-PD-1/PD-L1 therapy OR
Subjects who have previously received any anti-PD-1/PD-L1 therapy, alone or in combination. Subjects must have received at least 4 doses of anti-PD-1/PD-L1 therapy
Received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
Has received prior therapy with an anti-PD-1, anti-PD-L1, or anti-PD-L2 agent
